Naomi Deirdre Fisher, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renin | 35 | 2022 | 647 | 3.170 |
Why?
|
| Hypertension | 44 | 2024 | 8626 | 2.550 |
Why?
|
| Renin-Angiotensin System | 25 | 2017 | 737 | 1.930 |
Why?
|
| Angiotensin II | 27 | 2017 | 844 | 1.680 |
Why?
|
| Renal Circulation | 26 | 2017 | 289 | 1.640 |
Why?
|
| Cacao | 7 | 2013 | 98 | 1.500 |
Why?
|
| Blood Pressure | 33 | 2024 | 8532 | 1.200 |
Why?
|
| Flavonoids | 5 | 2012 | 448 | 1.090 |
Why?
|
| Sympathectomy | 6 | 2024 | 73 | 1.030 |
Why?
|
| Fumarates | 6 | 2016 | 132 | 0.990 |
Why?
|
| Captopril | 17 | 2017 | 261 | 0.980 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 8 | 2023 | 254 | 0.930 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 21 | 2016 | 1514 | 0.900 |
Why?
|
| Kidney | 26 | 2024 | 7066 | 0.870 |
Why?
|
| Amides | 6 | 2016 | 455 | 0.870 |
Why?
|
| Antihypertensive Agents | 21 | 2024 | 2033 | 0.800 |
Why?
|
| Aldosterone | 19 | 2022 | 881 | 0.670 |
Why?
|
| Denervation | 5 | 2023 | 265 | 0.600 |
Why?
|
| Vasodilation | 10 | 2016 | 970 | 0.590 |
Why?
|
| Internet | 8 | 2001 | 3106 | 0.580 |
Why?
|
| Angiotensinogen | 8 | 2009 | 161 | 0.570 |
Why?
|
| Renal Plasma Flow | 5 | 2008 | 28 | 0.520 |
Why?
|
| Hypertension, Renal | 3 | 2005 | 131 | 0.510 |
Why?
|
| Cerebrovascular Circulation | 3 | 2013 | 2674 | 0.510 |
Why?
|
| Beverages | 3 | 2013 | 819 | 0.480 |
Why?
|
| Renal Artery | 5 | 2023 | 345 | 0.440 |
Why?
|
| Tetrazoles | 10 | 2011 | 920 | 0.430 |
Why?
|
| Telemedicine | 2 | 2023 | 3105 | 0.430 |
Why?
|
| Endothelium, Vascular | 5 | 2016 | 4427 | 0.430 |
Why?
|
| Dipeptides | 4 | 2005 | 387 | 0.420 |
Why?
|
| Program Development | 1 | 2019 | 1295 | 0.400 |
Why?
|
| Sodium, Dietary | 6 | 2010 | 426 | 0.390 |
Why?
|
| Angiotensin I | 4 | 2008 | 47 | 0.380 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2011 | 429 | 0.350 |
Why?
|
| Benzimidazoles | 7 | 2007 | 864 | 0.340 |
Why?
|
| Adrenal Glands | 4 | 2002 | 558 | 0.340 |
Why?
|
| Uric Acid | 3 | 2017 | 809 | 0.330 |
Why?
|
| Diet, Sodium-Restricted | 9 | 2007 | 291 | 0.320 |
Why?
|
| Vitamin D | 5 | 2017 | 3272 | 0.320 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2010 | 276 | 0.310 |
Why?
|
| Hyperuricemia | 2 | 2017 | 221 | 0.300 |
Why?
|
| Disease Management | 1 | 2019 | 2535 | 0.290 |
Why?
|
| Reference Values | 15 | 2010 | 4908 | 0.290 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2013 | 952 | 0.280 |
Why?
|
| Probenecid | 2 | 2017 | 72 | 0.280 |
Why?
|
| Cushing Syndrome | 1 | 2008 | 241 | 0.270 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 4040 | 0.270 |
Why?
|
| Vasoconstrictor Agents | 6 | 2008 | 655 | 0.260 |
Why?
|
| Biphenyl Compounds | 10 | 2011 | 1019 | 0.260 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 5370 | 0.250 |
Why?
|
| Hypercalcemia | 1 | 2008 | 426 | 0.250 |
Why?
|
| Allopurinol | 2 | 2017 | 203 | 0.250 |
Why?
|
| Catechin | 1 | 2005 | 69 | 0.240 |
Why?
|
| Middle Aged | 59 | 2024 | 223009 | 0.240 |
Why?
|
| Overweight | 4 | 2024 | 2444 | 0.240 |
Why?
|
| Regional Blood Flow | 6 | 2010 | 1478 | 0.220 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 581 | 0.220 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 1426 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2007 | 3446 | 0.210 |
Why?
|
| Humans | 95 | 2024 | 765968 | 0.210 |
Why?
|
| Nitric Oxide | 3 | 2012 | 2143 | 0.200 |
Why?
|
| Mesothelioma | 1 | 2008 | 771 | 0.200 |
Why?
|
| Natriuresis | 5 | 2008 | 106 | 0.200 |
Why?
|
| Noise | 1 | 2024 | 296 | 0.200 |
Why?
|
| NG-Nitroarginine Methyl Ester | 4 | 2007 | 261 | 0.200 |
Why?
|
| American Heart Association | 2 | 2024 | 1047 | 0.190 |
Why?
|
| Female | 62 | 2024 | 396112 | 0.180 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 242 | 0.180 |
Why?
|
| Albuminuria | 3 | 2010 | 660 | 0.180 |
Why?
|
| Male | 58 | 2024 | 363698 | 0.180 |
Why?
|
| Arm | 1 | 2003 | 589 | 0.180 |
Why?
|
| Uricosuric Agents | 2 | 2017 | 30 | 0.180 |
Why?
|
| p-Aminohippuric Acid | 5 | 2010 | 36 | 0.170 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7123 | 0.170 |
Why?
|
| Feeding Behavior | 1 | 2012 | 3212 | 0.170 |
Why?
|
| Environmental Exposure | 2 | 2024 | 4544 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 3 | 2007 | 911 | 0.160 |
Why?
|
| Information Services | 1 | 2000 | 240 | 0.150 |
Why?
|
| Enzyme Inhibitors | 4 | 2007 | 3715 | 0.150 |
Why?
|
| Blood Flow Velocity | 2 | 2013 | 1381 | 0.150 |
Why?
|
| Adult | 54 | 2024 | 223044 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2018 | 647 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2098 | 0.140 |
Why?
|
| Vitamin D Deficiency | 2 | 2017 | 1348 | 0.140 |
Why?
|
| Hyperemia | 2 | 2012 | 224 | 0.140 |
Why?
|
| Vasoconstriction | 3 | 2006 | 594 | 0.140 |
Why?
|
| Manometry | 2 | 2012 | 457 | 0.140 |
Why?
|
| Treatment Outcome | 13 | 2024 | 65188 | 0.140 |
Why?
|
| Complementary Therapies | 1 | 2000 | 487 | 0.130 |
Why?
|
| Ergocalciferols | 1 | 2017 | 105 | 0.130 |
Why?
|
| Infusions, Intravenous | 4 | 2010 | 2229 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2016 | 10729 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2023 | 1149 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2008 | 4247 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 9 | 2016 | 2233 | 0.120 |
Why?
|
| Sodium | 3 | 2010 | 1591 | 0.120 |
Why?
|
| Body Mass Index | 7 | 2024 | 13039 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2009 | 153 | 0.120 |
Why?
|
| Carbamates | 1 | 2016 | 191 | 0.120 |
Why?
|
| Nurses | 1 | 2024 | 2505 | 0.120 |
Why?
|
| Pulsatile Flow | 2 | 2006 | 318 | 0.110 |
Why?
|
| Air Pollution | 2 | 2024 | 2380 | 0.110 |
Why?
|
| Thiazoles | 2 | 2005 | 1529 | 0.110 |
Why?
|
| Aging | 5 | 2006 | 8731 | 0.110 |
Why?
|
| Pandemics | 2 | 2023 | 8703 | 0.100 |
Why?
|
| Double-Blind Method | 6 | 2017 | 12437 | 0.100 |
Why?
|
| Diabetic Nephropathies | 4 | 2005 | 969 | 0.100 |
Why?
|
| Plethysmography | 1 | 2012 | 164 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1892 | 0.100 |
Why?
|
| Medical Informatics | 1 | 1999 | 745 | 0.100 |
Why?
|
| Vitamins | 2 | 2017 | 1630 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2023 | 2192 | 0.090 |
Why?
|
| Aged | 19 | 2024 | 171117 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 4 | 2011 | 303 | 0.090 |
Why?
|
| Sex Factors | 5 | 2007 | 10603 | 0.090 |
Why?
|
| Piperazines | 2 | 2005 | 2549 | 0.090 |
Why?
|
| Psychotherapy, Brief | 1 | 2011 | 118 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2024 | 54802 | 0.080 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15652 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 2334 | 0.080 |
Why?
|
| Candy | 1 | 2007 | 36 | 0.070 |
Why?
|
| Secretory Vesicles | 1 | 2008 | 127 | 0.070 |
Why?
|
| Genotype | 6 | 2008 | 13024 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2009 | 237 | 0.070 |
Why?
|
| Obesity | 3 | 2024 | 13076 | 0.070 |
Why?
|
| Flavanones | 1 | 2007 | 75 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2000 | 3956 | 0.070 |
Why?
|
| Hemodynamics | 7 | 2005 | 4184 | 0.070 |
Why?
|
| Postmenopause | 3 | 2009 | 2515 | 0.070 |
Why?
|
| Piperidines | 1 | 2016 | 1664 | 0.070 |
Why?
|
| Cough | 1 | 2011 | 597 | 0.070 |
Why?
|
| Edema | 1 | 2011 | 760 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2017 | 3425 | 0.070 |
Why?
|
| Enalapril | 2 | 2000 | 317 | 0.070 |
Why?
|
| Fruit | 1 | 2012 | 1166 | 0.070 |
Why?
|
| Vegetables | 1 | 2012 | 1199 | 0.070 |
Why?
|
| Color | 1 | 2007 | 299 | 0.070 |
Why?
|
| Brain | 1 | 2013 | 27171 | 0.070 |
Why?
|
| Genetic Linkage | 2 | 2005 | 2341 | 0.060 |
Why?
|
| Family Health | 2 | 2002 | 1253 | 0.060 |
Why?
|
| Hydrocortisone | 3 | 2001 | 1827 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2016 | 4015 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2011 | 1021 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2019 | 8733 | 0.060 |
Why?
|
| Public Health | 1 | 2018 | 2680 | 0.060 |
Why?
|
| Angiotensins | 1 | 2005 | 139 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 1881 | 0.060 |
Why?
|
| Food Labeling | 1 | 2007 | 181 | 0.060 |
Why?
|
| Medical Records | 1 | 2010 | 1409 | 0.060 |
Why?
|
| Brachial Artery | 2 | 2016 | 375 | 0.060 |
Why?
|
| Blood Volume | 1 | 2006 | 542 | 0.060 |
Why?
|
| Dementia, Vascular | 1 | 2006 | 126 | 0.060 |
Why?
|
| Age Factors | 5 | 2008 | 18380 | 0.060 |
Why?
|
| Systole | 2 | 2003 | 935 | 0.060 |
Why?
|
| Diastole | 2 | 2003 | 785 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 2222 | 0.060 |
Why?
|
| United States | 6 | 2024 | 72903 | 0.050 |
Why?
|
| Pulse | 1 | 2003 | 215 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 753 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4300 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2011 | 12240 | 0.050 |
Why?
|
| Adolescent | 11 | 2024 | 88835 | 0.050 |
Why?
|
| Fingers | 1 | 2006 | 509 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 804 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 655 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 559 | 0.050 |
Why?
|
| Phenotype | 6 | 2008 | 16721 | 0.050 |
Why?
|
| Linear Models | 3 | 2007 | 5876 | 0.050 |
Why?
|
| Boston | 3 | 2024 | 9338 | 0.050 |
Why?
|
| Homeostasis | 2 | 2010 | 3336 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2007 | 1602 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 15398 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2001 | 103 | 0.050 |
Why?
|
| Mast Cells | 1 | 2008 | 1412 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2001 | 61 | 0.050 |
Why?
|
| Lisinopril | 1 | 2001 | 60 | 0.040 |
Why?
|
| Blood Glucose | 3 | 2007 | 6424 | 0.040 |
Why?
|
| Potassium | 2 | 2002 | 1311 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 568 | 0.040 |
Why?
|
| Kidney Function Tests | 3 | 2009 | 683 | 0.040 |
Why?
|
| Renal Veins | 1 | 2000 | 103 | 0.040 |
Why?
|
| Drug Design | 1 | 2005 | 1042 | 0.040 |
Why?
|
| Alcoholism | 1 | 2010 | 1975 | 0.040 |
Why?
|
| Risk Factors | 9 | 2024 | 74840 | 0.040 |
Why?
|
| MEDLINE | 1 | 1999 | 120 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2000 | 298 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 988 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4255 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2002 | 1061 | 0.040 |
Why?
|
| Acrylates | 1 | 1997 | 75 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 1997 | 395 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2016 | 860 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2024 | 41649 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 7049 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 323 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 8041 | 0.030 |
Why?
|
| Young Adult | 5 | 2023 | 59889 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2016 | 176 | 0.030 |
Why?
|
| Time Factors | 5 | 2017 | 40065 | 0.030 |
Why?
|
| Diabetes Mellitus | 3 | 2011 | 5891 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5446 | 0.030 |
Why?
|
| Demography | 1 | 1999 | 1641 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2024 | 2116 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 460 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1589 | 0.030 |
Why?
|
| Health Education | 1 | 2001 | 1060 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2018 | 5993 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 81514 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 12509 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 1458 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 2393 | 0.030 |
Why?
|
| Exercise | 1 | 2010 | 5937 | 0.030 |
Why?
|
| Thiophenes | 1 | 1997 | 569 | 0.030 |
Why?
|
| Peptides | 1 | 2005 | 4331 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 26318 | 0.030 |
Why?
|
| Premenopause | 1 | 1997 | 1037 | 0.030 |
Why?
|
| Menopause | 2 | 2000 | 1659 | 0.030 |
Why?
|
| Publishing | 1 | 2000 | 835 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3202 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 616 | 0.020 |
Why?
|
| Glucose | 1 | 2003 | 4335 | 0.020 |
Why?
|
| Imidazoles | 1 | 1997 | 1162 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 1991 | 101 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2024 | 2788 | 0.020 |
Why?
|
| Syndrome | 1 | 1997 | 3271 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2024 | 2923 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2008 | 22223 | 0.020 |
Why?
|
| Incidence | 2 | 2024 | 21480 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2011 | 163 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 8086 | 0.020 |
Why?
|
| Creatinine | 2 | 2008 | 1915 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2927 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2000 | 2643 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 16047 | 0.020 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2008 | 13 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 4850 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 812 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6309 | 0.020 |
Why?
|
| Creatine | 1 | 2010 | 424 | 0.020 |
Why?
|
| Prevalence | 1 | 2024 | 15842 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 2686 | 0.020 |
Why?
|
| Culture Media | 1 | 2008 | 890 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1999 | 3278 | 0.020 |
Why?
|
| Inulin | 2 | 1999 | 67 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 526 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39193 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2000 | 8067 | 0.010 |
Why?
|
| Gastroparesis | 1 | 2007 | 143 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 59489 | 0.010 |
Why?
|
| Ethanol | 1 | 2011 | 1323 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2006 | 576 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 325 | 0.010 |
Why?
|
| Infertility | 1 | 2011 | 654 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 388 | 0.010 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 408 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 7425 | 0.010 |
Why?
|
| Animals | 4 | 2001 | 168764 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2007 | 770 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 805 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 14652 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3432 | 0.010 |
Why?
|
| France | 1 | 2003 | 495 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3318 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2011 | 1582 | 0.010 |
Why?
|
| Italy | 1 | 2003 | 854 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 14071 | 0.010 |
Why?
|
| Motor Activity | 1 | 2010 | 2704 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2000 | 311 | 0.010 |
Why?
|
| Zona Glomerulosa | 1 | 1999 | 87 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6322 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1999 | 262 | 0.010 |
Why?
|
| Complement Pathway, Alternative | 1 | 1998 | 106 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36532 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 3344 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 1299 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8875 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 621 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 2615 | 0.010 |
Why?
|
| Risk | 1 | 2009 | 9591 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2352 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2975 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10563 | 0.010 |
Why?
|
| Child | 1 | 2024 | 80564 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 1113 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 1591 | 0.010 |
Why?
|
| Posture | 1 | 1999 | 954 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12056 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 17075 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 30260 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 18071 | 0.000 |
Why?
|
| Models, Biological | 1 | 2002 | 9443 | 0.000 |
Why?
|
| Heart | 1 | 1998 | 4414 | 0.000 |
Why?
|
| Insulin | 1 | 1999 | 6599 | 0.000 |
Why?
|